

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 2, 2025

**AngioDynamics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**000-50761**  
(Commission File Number)

**11-3146460**  
(IRS Employer Identification No.)

**14 Plaza Drive, Latham, New York**  
(Address of Principal Executive Offices)

**12110**  
(Zip Code)

**(518) 795-1400**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class  
Common Stock, par value \$0.01 per share

Trading Symbol(s)  
ANGO

Name of each exchange on which registered  
NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On April 2, 2025, AngioDynamics, Inc. (“AngioDynamics”) will host the virtual Cardiovascular Investor Event. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

**Forward-Looking Statements**

This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

---

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits.*

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	Presentation slides for the Cardiovascular Investor Event, dated April 2, 2025.
104	Cover Page Interactive Data file (embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.  
(Registrant)

Date: April 2, 2025

By: /s/ Lawrence T. Weiss  
Name: Lawrence T. Weiss  
Title: Senior Vice President, Chief Legal Officer and Corporate Secretary

---

AURYON

ANGIOVAC

  
ALPHAVAC



# Cardiovascular

INVESTOR EVENT

**Shaping the Future of Cardiovascular Care:**  
Innovative Technologies. Improved Outcomes.

# Forward Looking Statements

## Forward Looking Statements

### Notice Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

# AngioDynamics

We are a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion, and customer centric sales performance.

## Cardiovascular Disease Causes 1 in 3 Deaths Globally<sup>1</sup>

523M diagnosed in 2020  
~19 million deaths<sup>2</sup>



## Cancer Causes 1 in 6 Deaths Globally<sup>3</sup>

19.3M diagnosed in 2020  
~10 million deaths<sup>5</sup>



 Cardiovascular



\$271M Fiscal 2024 Pro Forma Revenue<sup>5</sup>



Projected positive adj. EBITDA for FY2025<sup>5</sup>



2 Global Reporting Segments:  
Med Tech & Med Device



High growth Med Tech segment has grown to more than 40% of our total revenue<sup>5</sup>



Med Tech segment comprises 3 innovative platform technologies



Strong balance sheet

# AngioDynamics Summary

**Our Med Tech segment operates in key markets with unique technologies that deliver proven clinical outcomes.**

**We have a strong track record in portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing.**

**Our Med Device segment funds investments driving Med Tech growth.**


**We maintain a debt-free, strong balance sheet.**

**We expect to be Adj. EBITDA positive by FY2025 and cash flow positive by FY2026.**

**Our company is positioned for sustainable revenue growth and profit for years to come.**

# AngioDynamics Cardiovascular Portfolio

Differentiated technologies and a comprehensive portfolio enable us to be a strong competitor within high growth Cardiovascular Disease market




\* Management estimates & industry sources



# AngioDynamics

Our demonstrated successful execution in portfolio optimization, clinical and regulatory expansion, and product introductions drives growth...



## Med Tech Growth



## Cardiovascular Growth



ARTERIAL

AURYON



VENOUS

ANGIOVAC




ALPHAVAC




# Cardiovascular Arterial

With over 100,000 patients treated,<sup>6</sup> the Auryon Atherectomy System is projected in FY25 to exceed cumulative sales of \$180M since its September 2020 launch<sup>7</sup>

## MARKET DYNAMICS



## AURYON



### Treat all levels of calcification<sup>8-10</sup>

- Indicated for in-stent restenosis
- Treats above and below the knee (inc. below the ankle)

### Protective of vessel wall<sup>10-12</sup>

- Targeted biological reactions to address risk of perforations
- Built-in aspiration to address risk of embolization

### Ability to crack medial calcification<sup>21</sup>

- Shock waves break severe calcification, including medial arterial calcification
- Contributes to plaque modification that may help improve vessel compliance

### Designed for hospital and lab<sup>8-10,13</sup>

- Portable, 110V outlet, low noise, touch screen
- Debulk in fewer passes

# AURYON PERIPHERAL ARTERY DISEASE (PAD)

Auryon's solid-state laser technology has three times more affinity for lesion material than vessel walls and is capable of treating all lesions types ATK, BTK<sup>8-10</sup> & ISR<sup>™</sup>



Intuitive, Windows-based touch screen

355 nm wavelength

10-25 ns pulse width

Aspiration capability and indicated for ISR and to aspirate thrombus adjacent to stenosis

Foot pedal for hands-free activation



Ability to treat ISR, CTO, Calcified, Fibrotic, Thrombus and Soft Plaque lesions, ATK and BTK

No calibration and minimal warm up time

Small and portable (29 in x 13 in x 37 in)

Lightweight (198.45 lbs.)

110 V power outlet

 Cardiovascular

# Auryon Platform Technology

The Auryon System is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium<sup>10,11,14</sup>

## EFFICIENT

- Does not require calibration before each procedure
- May eliminate the need for multiple catheters for a single procedure
- Has the potential to debulk with minimal passes


## ADAPTABLE

- Treats all infrainguinal lesions<sup>8,9,10</sup>
- Treats infrainguinal lesions both above and below knee
- Has the ability to crack arterial calcium and prep the vessel<sup>21</sup>

## SMART

- Performs targeted biological reaction to address the risk of perforations<sup>22,23</sup>
- Nonreactive to contrast media allowing simultaneous ablation and observation of fluoroscopy images
- Includes built-in aspiration to address the risk of embolization\*

\*2 and 2.35 mm catheters



### Wavelength (nm)

The distance between 2 successive waves determines absorption rate and penetration depth

### Pulse width (ns)

The duration of each pulse determines level of diffusion

### Amplitude (mJ/mm<sup>2</sup>)

The height of the wave determines power<sup>10,11,13</sup>

## Why wavelength matters:<sup>15-18</sup>

- Each type of tissue interacts differently with a given wavelength<sup>7,8</sup>
- Longer wavelengths are absorbed at shallower depths than shorter wavelengths, resulting in lower photon energies<sup>7,8,9,10</sup>

## Importance of pulse width and amplitude<sup>15,17,19,20</sup>

- Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs<sup>10</sup>
- To localize the effects to the target tissue without thermal damage, the energy delivered needs to be faster than the time it takes for the heat to diffuse


# Auryon Platform Technology

The Auryon System's dual method of action: Micro-CT Study<sup>21</sup>

**CRACK** calcium & **REMOVE** plaque with **ONE** technology

**REMOVE**


Intimal  
Arterial Calcification



**Mechanism #1**

**Intimal Plaque/Calcium  
Debulking**

Works on removing different plaque morphologies, ATK – BTK and ISR



**MODIFY**



Medial  
Arterial Calcification



**Mechanism #2**

**Plaque/Calcium  
Modification**

Photomechanical shockwaves penetrate the medial wall to crack/modify plaque to bring pulsatility (elasticity/compliance) back to aging vessels.



This study was performed on cadavers, not on human subjects, and these results have not been validated in subsequent human research


# Auryon Platform Technology

The Auryon System's technology has demonstrated safety and efficacy in PAD and presents an opportunity to expand into additional disease states

## PERIPHERAL ARTERY DISEASE (PAD)



## CORONARY ARTERY DISEASE (CAD)



ARTERIAL

AURYON



VENOUS

ANGIOVAC



ALPHAVAC




The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extra-corporeal bypass for up to 6 hours.  
The Alphavac cannula is indicated for the non-surgical removal of thrombi or emboli and aspiration of contrast media and other fluids from the vasculature. It is intended for use in the venous system and for the treatment of Pulmonary Embolism.

# Cardiovascular Venous

Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity

## MARKET DYNAMICS



### Pulmonary Embolism (PE)

- Mechanical Thrombectomy is estimated to have penetrated ~25% of the TAM <sup>22</sup>
- Mechanical Thrombectomy is expected to grow ~16% in 2025 <sup>23</sup>

### Deep Vein Thrombosis (DVT)

- Mechanical Thrombectomy is estimated to have penetrated ~15% of the TAM <sup>22</sup>
- Mechanical Thrombectomy is expected to grow ~20% in 2025 <sup>23</sup>

### Right Heart

- Growth is driven by rising intravenous drug abuse, an aging population, and increased pacemaker prevalence
- More interventionalists embrace percutaneous techniques and the structural heart market is expanding

# Thrombus Management

All-purpose technology platforms targeted at peripheral and cardiovascular thrombolytic events, including small and large vessels



**RADIOPAQUE MARKERS**  
Better Tip Visibility

**LARGE-BORE ASPIRATION**  
42FR & 30FR Opening



**PROPRIETARY FUNNEL DESIGN**  
Allows for Significant Clot Removal

**MULTIPLE TIP ANGLES**  
20°, 85°, 180°

## ANGIOVAC

The **AngioVac** System allows for the **continuous aspiration** of embolic material such as thrombi and emboli from the venous system while **simultaneously reinfusing** the patient's own filtered blood to limit procedural blood loss.



## ALPHAVAC

The **AlphaVac** System allows for the **controlled aspiration** of embolic material such as thrombi and emboli from the venous system.



# AngioVac Technology

The only system that enables continuous aspiration and simultaneous reinfusion of blood, empowering physicians to treat more complex cases using minimally invasive techniques

## Aspiration & Simultaneous Reinfusion



- On-circuit aspiration provides surgical results via percutaneous access by simultaneously reinfusing blood back in the patient's body, minimizing blood loss.

## Proprietary Funnel



- Funnel tip design enables efficient clot aspiration and compression
- 18Fr (33Fr) & 22Fr (42Fr) options

- More than 100 publications on the use of the AngioVac system<sup>24</sup>
- Use of the device has been published for caval thrombi, cardiac masses and thrombi<sup>25</sup>


# ANGIO©VAC



30 min.



**Clot Removal**



**EMORY HOSPITAL – MIDTOWN**  
**Dr. Brent Keeling\* (CT)**

Actual procedure results, these images represent the experience of one institution and are not indicative of all procedural results.

\*Dr. Keeling is a paid consultant of AngioDynamics




**Cardiovascular**

# AlphaVac Technology

## Handle & Control Features



# ALPHAVAC



**MALE AND FEMALE CONNECTION**  
Ensures correct connection

**DIRECTIONAL LABELS**  
Cannula | Waste Bag

**ANGLED EXIT**  
Prevents large thrombus clog

**SPACER**  
Allows sterile blood path and confirms plunger passes shelf-life constraints

**ROBUST DESIGN**  
Enables smooth pulls with contemporary design

**SYRINGE BARREL**

**VOLUME LIMITING SWITCH**  
Intuitive location | Multiple glove sizes

**DURABLE LABELS**  
Visible in low light environments

**VACUUM LOCK**  
Controlled, single-hand design

**ANGLED HILT**  
Easy access to vacuum lock

**TEXTURED GRIP**  
Enhances grip control



# ALPHAVAC



Proprietary  
FUNNEL



Manual  
Aspiration  
HANDLE



Advanced - Large  
Bore Aspiration  
CANNULA



Complete  
SYSTEM

Cardiovascular



IU HEALTH  
Dr. Thomas Casciani (IR)  
& Dr. Sabah Butty\* (IR)

\*Dr. Butty is a paid consultant of AngioDynamics

Actual procedure results, these images represent the experience of one institution and are not indicative of all procedural results.

Only the AlphaVac F18<sup>®</sup> System is indicated for the treatment of pulmonary embolism (PE). The AlphaVac F22<sup>®</sup> and F22<sup>®</sup> Systems are not indicated for the treatment of PE.



# ALPHAVAC

# APEX-AV

## Pulmonary Embolism Indication



Only the AlphaVac F18<sup>85</sup> System is indicated for the treatment of pulmonary embolism (PE).  
The AlphaVac F22<sup>80</sup> and F22<sup>80</sup> Systems are not indicated for the treatment of PE.

# APEX – AV Pivotal Study

AlphaVac F18<sup>85</sup> received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies

## APEX-AV

Number of Sites **25 US Sites**  
Number of Patients **122**  
Timeline **Oct. 2022 – Dec 2023**

### Significant reduction in the RV/LV ratio<sup>26</sup>

- Significant improvement in the RV function
- 0% mortality rate<sup>29</sup>

### Significant reduction in clot burden<sup>26</sup>

- Large funnel size (33 Fr) may aid in reducing the clot burden

### Procedure efficiency

- 37.2 min mean procedure time<sup>29</sup>
- Atraumatic tip provides easy and efficient navigation in the Pas
- Ability to minimize blood loss<sup>30</sup>

	APEX (AlphaVac)	FLARE (FlowTriever)	EXTRACT-PE <sup>28</sup> (Indigo)
Reduction in Clot Burden	35.5%	9.3%	11.3%



Only the AlphaVac F18<sup>85</sup> System is indicated for the treatment of pulmonary embolism (PE).  
The AlphaVac F22<sup>89</sup> and F22<sup>90</sup> Systems are not indicated for the treatment of PE.

# AngioDynamics Summary

Our Med Tech segment operates in key markets with unique technologies that deliver proven clinical outcomes

We have a strong track record in portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing

Our Med Device segment funds investments driving Med Tech growth

We maintain a debt-free, strong balance sheet

We expect to be Adj. EBITDA positive by FY2025 and cash flow positive by FY2026

Our company is positioned for sustainable revenue growth and profit for years to come

AURYON

ANGIOVAC

ALPHAVAC



# Cardiovascular

INVESTOR EVENT

**Shaping the Future of Cardiovascular Care:**  
Innovative Technologies. Improved Outcomes.

---

